Nordea Investment Management Ab Exelixis, Inc. Transaction History

Nordea Investment Management Ab

$85.8 Billion
Q3 2024

A detailed history of Nordea Investment Management Ab transactions in Exelixis, Inc. stock. As of the latest transaction made, Nordea Investment Management Ab holds 222,017 shares of EXEL stock, worth $7.91 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

222,017

Previous 173,246 28.15%

Holding current value

$7.91 Million

Previous $3.89 Million 48.02%

% of portfolio

0.01%

Previous 0.0%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 05, 2024	BUY	$21.96 - $27.6 $1.07 Million - $1.35 Million	48,771 Added 28.15%	222,017 $5.76 Million
Q2 2024 Aug 08, 2024	SELL	$20.34 - $23.73 $590,795 - $689,261	-29,046 Reduced 14.36%	173,246 $3.89 Million
Q1 2024 May 02, 2024	BUY	$20.17 - $23.93 $600,743 - $712,731	29,784 Added 17.27%	202,292 $4.8 Million
Q4 2023 Jan 10, 2024	SELL	$19.25 - $24.13 $113,729 - $142,560	-5,908 Reduced 3.31%	172,508 $4.14 Million
Q3 2023 Nov 13, 2023	SELL	$19.04 - $22.74 $93,543 - $111,721	-4,913 Reduced 2.68%	178,416 $3.9 Million
Q2 2023 Jul 07, 2023	SELL	$18.17 - $20.48 $1.34 Million - $1.52 Million	-73,993 Reduced 28.76%	183,329 $3.5 Million
Q1 2023 Apr 19, 2023	SELL	$16.3 - $19.41 $55,599 - $66,207	-3,411 Reduced 1.31%	257,322 $4.99 Million
Q4 2022 Feb 08, 2023	SELL	$14.96 - $17.39 $164,200 - $190,872	-10,976 Reduced 4.04%	260,733 $4.18 Million
Q3 2022 Oct 19, 2022	SELL	$15.68 - $22.27 $46,036 - $65,384	-2,936 Reduced 1.07%	271,709 $4.34 Million
Q2 2022 Aug 09, 2022	SELL	$17.44 - $23.16 $504,643 - $670,157	-28,936 Reduced 9.53%	274,645 $5.66 Million
Q1 2022 Apr 11, 2022	BUY	$17.03 - $22.67 $54,291 - $72,271	3,188 Added 1.06%	303,581 $6.83 Million
Q4 2021 Jan 20, 2022	SELL	$15.84 - $21.88 $60,635 - $83,756	-3,828 Reduced 1.26%	300,393 $5.59 Million
Q3 2021 Nov 01, 2021	SELL	$16.3 - $21.14 $4.96 Million - $6.43 Million	-304,221 Reduced 50.0%	304,221 $6.4 Million
Q3 2021 Nov 01, 2021	BUY	$16.3 - $21.14 $5.02 Million - $6.51 Million	307,777 Added 102.37%	608,442 $12.9 Million
Q2 2021 Jul 16, 2021	BUY	$17.95 - $25.56 $452,734 - $644,674	25,222 Added 9.16%	300,665 $5.48 Million
Q1 2021 May 17, 2021	SELL	$20.53 - $25.22 $380,420 - $467,326	-18,530 Reduced 6.3%	275,443 $6.21 Million
Q4 2020 Feb 12, 2021	BUY	$18.39 - $24.8 $357,483 - $482,087	19,439 Added 7.08%	293,973 $5.9 Million
Q3 2020 Nov 09, 2020	SELL	$20.67 - $26.94 $5.62 Million - $7.32 Million	-271,662 Reduced 49.74%	274,534 $6.77 Million
Q2 2020 Aug 13, 2020	BUY	$16.46 - $27.42 $4.48 Million - $7.46 Million	272,019 Added 99.21%	546,196 $13 Million
Q1 2020 May 15, 2020	BUY	$14.46 - $21.8 $176,440 - $266,003	12,202 Added 4.66%	274,177 $4.87 Million
Q4 2019 Feb 11, 2020	BUY	$15.15 - $18.89 $82,249 - $102,553	5,429 Added 2.12%	261,975 $4.67 Million
Q3 2019 Nov 13, 2019	BUY	$17.68 - $22.65 $7,354 - $9,422	416 Added 0.16%	256,546 $4.63 Million
Q2 2019 Aug 14, 2019	SELL	$18.93 - $24.75 $30,893 - $40,392	-1,632 Reduced 0.63%	256,130 $5.47 Million
Q1 2019 May 20, 2019	SELL	$19.6 - $24.76 $130,790 - $165,223	-6,673 Reduced 2.52%	257,762 $6.14 Million
Q4 2018 Feb 14, 2019	BUY	$13.65 - $21.8 $572,685 - $914,619	41,955 Added 18.86%	264,435 $5.2 Million
Q3 2018 Nov 14, 2018	BUY	$15.87 - $22.4 $1.09 Million - $1.54 Million	68,537 Added 44.52%	222,480 $3.94 Million
Q2 2018 Aug 13, 2018	BUY	$18.56 - $22.45 $873,080 - $1.06 Million	47,041 Added 44.0%	153,943 $3.31 Million
Q1 2018 May 14, 2018	BUY	$22.15 - $31.89 $400,604 - $576,762	18,086 Added 20.36%	106,902 $2.37 Million
Q4 2017 Feb 12, 2018	BUY	$24.23 - $30.93 $244,504 - $312,114	10,091 Added 12.82%	88,816 $2.7 Million
Q3 2017 Nov 09, 2017	BUY	$23.35 - $29.24 $1.84 Million - $2.3 Million	78,725	78,725 $1.91 Million

Others Institutions Holding EXEL

# of Institutions

501

Shares Held

244M

Call Options Held

2.54M

Put Options Held

2.29M

View Full List

About EXELIXIS, INC.

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.5B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

More about EXEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Nordea Investment Management Ab, based on Form 13F filings with the SEC.

News

Stay updated on Nordea Investment Management Ab with notifications on news.

Account

Nordea Investment Management Ab Exelixis, Inc. Transaction History